Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.

Damiano BaronciniMauro ZaffaroniLucia MoiolaLorena LoreficeGiuseppe FenuPietro IaffaldanoMarta SimoneFulvia FanelliFrancesco PattiEmanuele D'AmicoMarco CapobiancoAntonio BertolottoPaolo GalloMonica MargoniSilvia MianteNicoletta MilaniMaria Pia AmatoIsabella RighiniPaolo BellantonioCinzia ScandellariGianfranco CostantinoElio ScarpiniRoberto BergamaschiGiulia MallucciGiancarlo ComiAngelo Ghezzi

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2018)

Pediatric-MS patients benefited from interferons/copaxone, but the majority had to switch to more powerful drugs. Starting therapy before 12 years of age could lead to a more favorable outcome.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
mass spectrometry
prognostic factors
multiple sclerosis
peritoneal dialysis
clinical trial
randomized controlled trial
ms ms
mesenchymal stem cells
patient reported